Haplo-cord HCT offered improved 2-year OS (72.7% vs 61.0%) and DFS (67.0% vs 49.6%) compared with haplo HCT alone.
The European Society for Blood and Marrow Transplantation (EBMT) has released its ninth special report on indications for ...